GT Biopharma Files 8-K
Ticker: GTBP · Form: 8-K · Filed: Jun 27, 2024 · CIK: 109657
Sentiment: neutral
Topics: corporate-events, filing, financials
TL;DR
GT Biopharma filed an 8-K on 6/27/24. Nothing major, just corporate housekeeping.
AI Summary
GT Biopharma, Inc. filed an 8-K on June 27, 2024, reporting other events and financial statements. The company, formerly known as OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/, is incorporated in Delaware and has its principal executive offices in Brisbane, CA.
Why It Matters
This filing provides an update on GT Biopharma's corporate activities and financial reporting, which is important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for other events and financial statements, not indicating any significant new risks or material adverse changes.
Key Players & Entities
- GT Biopharma, Inc. (company) — Registrant
- June 27, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 8000 Marina Blvd., Suite 100 (address) — Principal Executive Offices
- Brisbane, CA (location) — City and State of Principal Executive Offices
- OXIS INTERNATIONAL INC (company) — Former Company Name
- DDI PHARMACEUTICALS INC (company) — Former Company Name
- DIAGNOSTIC DATA INC /DE/ (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing for GT Biopharma, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of June 27, 2024.
When was this 8-K report filed by GT Biopharma, Inc.?
The 8-K report was filed on June 27, 2024.
What are the former names of GT Biopharma, Inc. mentioned in the filing?
The filing mentions former names including OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/.
Where are GT Biopharma, Inc.'s principal executive offices located?
GT Biopharma, Inc.'s principal executive offices are located at 8000 Marina Blvd., Suite 100, Brisbane, CA 94005.
Under which section of the Securities Exchange Act of 1934 is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-06-27 09:34:59
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value GTBP The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001493152-24-025382.txt ( ) — 242KB
- gtbp-20240627.xsd (EX-101.SCH) — 3KB
- gtbp-20240627_lab.xml (EX-101.LAB) — 33KB
- gtbp-20240627_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GT BIOPHARMA, INC. Date: June 27, 2024 By: /s/ Alan Urban Alan Urban Chief Financial Officer